News >

Ibrutinib Receives Breakthrough Designations for Mantle Cell Lymphoma and Waldenström's Macroglobulinemia

Ben Leach
Published: Wednesday, Feb 13, 2013

Paul Stoffels, MD

Paul Stoffels, MD

The investigational agent ibrutinib was granted “Breakthrough Therapy Designations” by the FDA as a singular therapy for a pair of B-cell malignancies: relapsed or refractory mantle cell lymphoma (MCL) and Waldenström’s macroglobulinemia.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication